Evidence mapPaperPMID 41358458Full record

Trial reportJournal of cosmetic dermatology2025

A Prospective, Randomized, Double-Blind, Split-Face Trial Evaluating the Effects of Pre-Conditioning With a TriHex Technology Serum Nectar 2.0 Versus a Vehicle in Subjects Undergoing Elective Facelift Surgery.

Alan D Widgerow, Amir Moradi, Reza Sadrian, Kiersten Riedler, Faiza Shafiq, Tiffany Robison

Abstract readRandomized Controlled TrialComparative Study
In one paragraph

Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alan D WidgerowDivision Chief Research, Professor Plastic Surgery, Center for Tissue Engineering, University of California, Irvine, California, USA.ORCID https://orcid.org/0000-0002-5705-8073
Amir MoradiPacific Clinical Innovations, Vista, California, USA.ORCID https://orcid.org/0000-0002-4896-5296
Reza SadrianSadrian Plastic Surgery, La Jolla, California, USA.
Kiersten RiedlerLa Jolla Cosmetic Surgery Centre, La Jolla, California, USA.
Faiza ShafiqAlastin Skincare, Inc., a Galderma Company, Carlsbad, California, USA.
Tiffany RobisonAlastin Skincare, Inc., a Galderma Company, Carlsbad, California, USA.

Funding

Alastin Skincare Inc, a Galderma company
6 · The paper itself

Abstract

backgroundPreconditioning of skin prior to procedures with the Alastin TriHex Technology has been demonstrated to enhance procedure outcomes. Alastin Regenerating Skin Nectar with TriHex Technology Serum (Alastin Skincare Inc. Carlsbad, CA) has undergone reformulation to include an added Octapeptide-45 for improving post-surgical outcomes and healing through pre-conditioning. A 5-week clinical trial was conducted to demonstrate efficacy and safety for post-surgical skin wound healing (following pre-conditioning), and overall skin health. In particular, molecular and cellular changes were documented, histologically comparing the treated side against the vehicle on the opposite side.

methodsA randomized, double-blinded, split-face, comparative study was conducted in 5 patients to evaluate the effects of pre-conditioning with a TriHex Technology Serum 2.0 (Nectar 2.0) compared to vehicle in subjects undergoing elective facelift surgery. Patient questionnaires and investigator assessments were undertaken, and baseline biopsies were taken from both sides 4 weeks prior to surgery. Following the facelift surgery, collected skin samples from each side of the face were analyzed for histological changes comparing pre (screening) and post (4 weeks) of pre-conditioning use of study topicals by an independent dermatopathologist using multiple staining techniques.

resultsInvestigator assessment with facial aesthetic clinical grading scale demonstrated greater improvements for the Nectar 2.0 treatment side compared to vehicle at Day 7 from screening for all assessed parameters: skin dullness, fine lines, tactile roughness, global photodamage. Investigator healing assessments demonstrated improved Healing on the Nectar 2.0 treatment side compared to vehicle, related to erythema, edema, and crusting parameters. Histological differences between the two sides were significant with major changes in extracellular matrix composition involving collagen, elastin and hyaluronic acid production and reversal of solar elastosis, all Evident only on the Nectar 2.0 treated side.

conclusionA randomized, double-blinded, split-face, comparative study with Alastin Regenerating Skin Nectar with TriHex + Technology Serum 2.0 revealed that pre-conditioning resulted in significant improvement in healing, global skin health and histological results with marked remodeling of the ECM being observed in all patients. A short period of pre-conditioning can have substantial effects on skin health and procedure outcomes.

Indexed as

OligopeptidesRhytidoplastyWound HealingAdultAgedDouble-Blind MethodElective Surgical ProceduresFemaleHumansMaleMiddle AgedProspective StudiesSkinSkin AgingTreatment OutcomeOligopeptides

Identifiers

PMID41358458
PMCPMC12683705

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.